Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
Gaurav Goyal(Glocal University), Ronald S. Go(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Thomas M. Habermann(Mayo Clinic in Arizona), Robert Vassallo(Mayo Clinic), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), N. Nora Bennani(Mayo Clinic in Arizona), Mrinal M. Patnaik(Mayo Clinic), Gita Thanarajasingam(Mayo Clinic in Arizona), Jason R. Young(WinnMed), Karen L. Rech(Mayo Clinic in Arizona), Sameer A. Parikh(Mayo Clinic), Aishwarya Ravindran(Mayo Clinic in Arizona), Taimur Sher(Mayo Clinic in Florida)
Cited by 215
Related Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697